Core Insights - Anavex Life Sciences Corp. announced new findings for blarcamesine, an oral small molecule for the potential treatment of early Alzheimer's disease, demonstrating significant cognitive benefits compared to the ADNI control group [1][2][5] Group 1: Clinical Trial Results - In the intent-to-treat population, blarcamesine showed a significant reduction in cognitive decline at 48 weeks with a mean change from baseline ADAS-Cog13 total score of -2.68 points (p < 0.0001) compared to the ADNI control group [4] - At 96 weeks, the difference in mean change in ADAS-Cog13 total score was -6.41 points (p < 0.0001), and this difference increased to -12.78 points at 144 weeks (p < 0.0001) [5][7] - The treatment resulted in 77.4 weeks (approximately 17.8 months) of 'time saved' in the ITT population compared to the ADNI control group, emphasizing the real-world impact of the treatment on patients' daily lives [9][10] Group 2: Mechanism of Action - Blarcamesine was confirmed to restore impaired autophagy, acting upstream of amyloid-beta and tau pathologies, which are critical in Alzheimer's disease progression [11][12] - The mechanism involves SIGMAR1 activation, enhancing autophagic flux and proteostasis capacity, which may ameliorate symptoms associated with protein aggregation [12] Group 3: Company Perspective - The company expressed optimism about the significant clinical improvements and the favorable safety profile of blarcamesine, highlighting its potential as a scalable and patient-friendly treatment option for early Alzheimer's disease [13] - Anavex plans to present this new data at international Alzheimer's disease conferences, aiming to advance treatment strategies for this chronic condition [13]

CHICAGO and MINNEAPOLIS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo”) (CSE: VREO; OTCQX: VREOF) and Verano Holdings Corp. (“Verano”, Vireo and Verano, each a “Company”) (Cboe CA: VRNO) (OTCQX: VRNOF) today announced that they have reached a comprehensive settlement (the “Settlement Agreement”) dismissing all outstanding litigation matters between the two Companies that are pending before the Supreme Court of British Columbia, Canada. The terms of the Settlement Agreement were approved by th ...

Core Insights - Southern Michigan Bancorp, Inc. reported a net income of $3,019,000 for Q3 2025, representing a 16.70% increase from $2,586,000 in Q3 2024 [1] - For the first nine months of 2025, net income reached $9,303,000, a 20.0% increase compared to $7,751,000 in the same period of 2024 [1] Financial Performance - The annualized return on average assets improved to 0.79% for the nine months ended September 30, 2025, up from 0.70% for the same period in 2024 [2] - The annualized return on average equity increased to 11.00% in the first nine months of 2025, compared to 10.18% in the first nine months of 2024 [2] - The tax equivalent net interest margin rose to 3.21% for the nine-month period ending September 30, 2025, compared to 2.94% for the same period in 2024 [2] Operational Highlights - The company achieved record levels in loans, deposits, and total assets by the end of the quarter, as stated by the CEO [3] - The allowance for credit losses was $14,410,000, or 1.17% of loans, as of September 30, 2025 [3] - Non-performing loans as a percentage of total loans increased to 1.03% as of September 30, 2025, from 0.08% as of December 31, 2024 [3] Balance Sheet Overview - Total assets reached $1,665,097,000 as of September 30, 2025, compared to $1,496,555,000 as of December 31, 2024 [6][7] - Total deposits increased to $1,394,932,000 in September 2025, up from $1,251,795,000 in December 2024 [7] - Shareholders' equity rose to $117,778,000 as of September 30, 2025, compared to $107,223,000 at the end of 2024 [7] Income Statement Summary - Total interest income for Q3 2025 was $21,269,000, compared to $19,531,000 in Q3 2024 [8][9] - Net interest income after provision for credit losses was $10,886,000 for Q3 2025, up from $9,968,000 in Q3 2024 [9] - Non-interest income totaled $2,618,000 for Q3 2025, compared to $2,172,000 in Q3 2024 [9]

The intersection of Blue Gold’s strategy with global adoption of blockchain technology and responsible regulation, a renewed focus on gold as a store of value, and a growing demand for real assets as credible alternatives to fiat currenciesNEW YORK, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Blue Gold Limited (Nasdaq: BGL) ("Blue Gold" or the “Company”), a next-generation gold development and technology company, sets out its vision, mission and strategy to become a market leading vertically integrated gold compa ...

WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November. On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during t ...

Core Insights - GXO Logistics, Inc. announced organizational changes aimed at accelerating growth, simplifying structure, and enhancing execution [1][2] Leadership Changes - Michael Jacobs has been appointed as President of the Americas and Asia Pacific, effective November 3, bringing over 30 years of supply chain experience [2][3] - Jacobs previously held senior roles at Ferguson Enterprises, Keurig, and Toys "R" Us, focusing on supply chain transformation and automation [3][4] Management Structure Simplification - The management structure is being simplified, with the UK & Ireland and Continental Europe regions reporting directly to the CEO [5][6] - Richard Cawston, former President of Europe and Chief Revenue Officer, will leave the company but will assist in the transition until a new Chief Commercial Officer is appointed [5][6] Operational Excellence - A new Chief Operating Officer role is being established to drive operational excellence through standardized global execution [6] Company Overview - GXO is the largest pure-play contract logistics provider, with over 150,000 team members across more than 1,000 facilities, totaling over 200 million square feet [8] - The company focuses on e-commerce, automation, and outsourcing, serving leading blue-chip companies with advanced supply chain solutions [8]

The acquisition is non-dilutive for shareholders and expected to generate over $30 million in annual premiums, with $8 million in annual revenues over the next twelve months after closing, and a 25% net income margin on a standalone basisNEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Roadzen Inc. (Nasdaq: RDZN), a global leader in AI at the intersection of insurance and mobility, today announced that it has signed a definitive agreement to acquire majority control of a commercial auto insurance broker and mana ...

CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 11:30 a.m. ET. Additionally, management will be available for one-on-one meetin ...

Q3-2025 Net Income of $6.7 million, EBITDA1 of $18.7 million and Free Cash Flow to Equity1 of $11.1 millionFull Debt Repayment Achieved in October 2025Quarterly dividend Increased by 33%Quarterly Dividend of Cdn$0.04 Declared VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce a strong financial performance for the three months ended September 30, 2025 (“Q3-2025”) and the full repayment of corporat ...

Core Insights - OraSure Technologies, Inc. has scheduled its earnings conference call for Q3 2025 financial results on November 5, 2025, at 5 p.m. ET [1] - A webcast of the conference call will be available on OraSure's investor relations page, with access instructions provided [2] Company Overview - OraSure Technologies, Inc. focuses on transforming health through actionable insights and decentralizing diagnostics to enhance healthcare access [3] - The company, along with its subsidiaries DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in rapid diagnostic tests and sample collection solutions [3] - OraSure's products are distributed globally to various sectors, including clinical laboratories, hospitals, and direct consumers [3]